not sure what outcome you expect from this exercise.
CHM is a thinly capitalised micro cap - if you are after best practice for corporate governance and compliance, suggest you invest in a banking stock.
Sure - SP is under pressure, and there have been a few wobbles - but we are also making great strides in the clinic. With CHM CDH17 there may be a number of world firsts:
- proven efficacy against GI cancer targeting CDH17 antigen
- CART with durable persistence that works against solid tumours
- very long patent life
this could make the company and its assets very, very valuable to big pharma.
Add to My Watchlist
What is My Watchlist?
